Core Viewpoint - The company, MicroTech Medical-B (02235), has received approval for its LinX continuous glucose monitoring system in India, marking a significant entry into a high-growth market with substantial diabetes prevalence [1][2]. Group 1: Product Approval and Market Entry - The LinX system has been approved for continuous glucose monitoring in adults in India, enhancing the company's international market presence [1]. - The system has already been integrated into healthcare systems across multiple European countries and has gained access in emerging markets in the Middle East, Asia-Pacific, and South America [1]. Group 2: Market Potential and Demand - India has approximately 89.83 million diabetes patients aged 20-79, with a prevalence rate of 9.5%, ranking second globally in terms of patient numbers [1]. - The country also faces a significant increase in prediabetes rates and a concerning trend of younger individuals being affected, indicating a substantial demand for digital and intelligent diabetes management solutions [1]. Group 3: Future Focus - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [2].
微泰医疗-B(02235)持续葡萄糖监测系统海外获批 将极大拓宽海外市场覆盖半径